Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis
Status:
Unknown status
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare and evaluate the efficacy of subcutaneous (40mg)
adalimumab biweekly injections to intravitreal adalimumab (1.5 mg/ 0.03 mL) administration,
given at zero, 2 weeks then every four weeks, in subjects with active non-infectious
intermediate-, posterior-, or pan-uveitis.